Shares of Gilead Sciences jumped nearly 14% and hit a new high Monday after the biotech reported that its hepatitis C regimen produced a 100% cure rate in a late-stage trial. At the annual Liver Meeting in Boston, Gilead (GILD) reported that all 25 patients in the study showed a sustained virological response after a 12-week course of treatment with standard oral treatment ribavirin along with Gilead's two drug candidates, GS-5885